Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
Tóm tắt
Chemical crosslinking is the most straightforward method to produce bispecific antibodies (BsAb) for arming ex vivo activated cytotoxic T lymphocytes. However, heterogeneous polymers are produced by chemical crosslinking. Currently, it is not known under what circumstances or to what extent further purification is needed. In this study, we purified Traut’s Reagent-Sulfo-SMCC crosslinked anti-CD3 × anti-HER2 by size-exclusion column chromatography and compared the capacity of the crude and the purified forms of the BsAb in enhancing cytokine-induced killer (CIK) cell-mediated cytotoxicity in vitro. We found that the purified BsAb assisted CIK cells more efficiently than the crude form only when the spontaneous cytotoxicity of the CIK cells was relatively low; otherwise, the two forms performed almost identically. For the CIK cells of low spontaneous cytotoxicity, purified BsAb is a more powerful substitute for crude BsAb in enhancing their killing efficacy. However, that purification of BsAb is not necessary for robust CIK cells. This phenomenon also corroborates that CIK-mediated cytotoxicity is highly dependent on cell contact.
Tài liệu tham khảo
Karpovsky B, Titus JA, Stephany DA, Segal DM: Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med. 1984, 160: 1686-1701. 10.1084/jem.160.6.1686
Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM: Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985, 316: 354-356. 10.1038/316354a0
Staerz UD, Kanagawa O, Bevan MJ: Hybrid antibodies can target sites for attack by T cells. Nature. 1985, 314: 628-631. 10.1038/314628a0
Staerz UD, Bevan MJ: Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U S A. 1986, 83: 1453-1457. 10.1073/pnas.83.5.1453
Lanzavecchia A, Scheidegger D: The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987, 17: 105-111. 10.1002/eji.1830170118
Moller SA, Reisfeld RA: Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes. Cancer Immunol Immunother. 1991, 33: 210-216. 10.1007/BF01744939
Kuppen PJ, Eggermont AM, Smits KM, van Eendenburg JD, Lazeroms SP, van de Velde CJ, Fleuren GJ: The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531. Cancer Immunol Immunother. 1993, 36: 403-408. 10.1007/BF01742257
Azuma A, Yagita H, Okumura K, Kudoh S, Niitani H: Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibody. Cancer Immunol Immunother. 1994, 38: 294-298.
Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG: Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu + tumors. J Hematother Stem Cell Res. 2001, 10: 247-260. 10.1089/15258160151134944
Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD, Kornacker M: Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother. 2007, 56: 1911-1920. 10.1007/s00262-007-0333-0
Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ: Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells. Clin Breast Cancer. 2003, 4: 212-217.
Holliger P, Prospero T, Winter G: “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993, 90: 6444-6448. 10.1073/pnas.90.14.6444
Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW: Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 2013, 110: 5145-5150. 10.1073/pnas.1220145110
Lum LG, Ramesh M, Thakur A, Mitra S, Deol A, Uberti JP, Pellett PE: Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 x anti-CMV bispecific antibody. Biol Blood Marrow Transplant. 2012, 18: 1012-1022. 10.1016/j.bbmt.2012.01.022
Thakur A, Schalk D, Sarkar SH, Al-Khadimi Z, Sarkar FH, Lum LG: A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2012, 61: 497-509. 10.1007/s00262-011-1116-1
Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG: Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012, 59: 1198-1205. 10.1002/pbc.24237
Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, Wicha MS, Chang AE, Li Q: Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 2013, 149: 156-168. 10.1016/j.clim.2013.07.006
Mezzanzanica D, Canevari S, Menard S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI: Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer. 1988, 41: 609-615. 10.1002/ijc.2910410422
Kiewe P, Thiel E: Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008, 17: 1553-1558. 10.1517/13543784.17.10.1553
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991, 174: 139-149. 10.1084/jem.174.1.139
Linn YC, Lau LC, Hui KM: Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002, 116: 78-86. 10.1046/j.1365-2141.2002.03247.x
Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993, 21: 1673-1679.
Lu PH, Negrin RS: A novel population of expanded human CD3 + CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994, 153: 1687-1696.
Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS: Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994, 87: 453-458. 10.1111/j.1365-2141.1994.tb08297.x
Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012, 9: 671-675. 10.1038/nmeth.2089